Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNITUDE: NTLA-2001 in ATTR-CM
NCT06128629Phase 3Recruiting
- Sponsor
- Intellia Therapeutics
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 26
01
Overview
A Phase 3 trial of nexiguran ziclumeran in transthyretin amyloidosis (ATTR), sponsored by Intellia Therapeutics. Started Dec 2023; status: recruiting.
02
Drugs
nexiguran ziclumeran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT06128629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06128629.